ReviewCardiac failure review2023
Biomarkers to Improve Decision-making in Acute Heart Failure.
Review in Cardiac failure review, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Low serum chloride concentration and the in-hospital mortality of patients with acute decompensated heart failure: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Hyperuricemia Reflects Cardiometabolic Burden Rather than Left Ventricular Systolic Dysfunction Across Heart Failure Phenotypes: Insights from a Real-World Acute Heart Failure Cohort.Journal of clinical medicine · 2026Article
- Association of NT-proBNP With Clinical Outcomes in Patients Undergoing Transcatheter Tricuspid Valve Intervention.JACC. Advances · 2026Article
- Prognostic impact of platelet count trajectories in acute decompensated heart failure: a retrospective cohort analysis.BMC cardiovascular disorders · 2026Article
- Prognostic Value of a Low-Cost LDH-Hemoglobin-Albumin Biomarker Panel in Acute Heart Failure: A Real-World Cohort from a Resource-Limited Setting.Biomedicines · 2026Article
- Impact of Predischarge NT-proBNP on Treatment Optimisation in Acute Heart Failure.International journal of molecular sciences · 2026Observational
- The Right Approach: Power of Biomarkers in the Assessment and Management of Right Ventricular Dysfunction.International journal of molecular sciences · 2025Review
- Assessment of platelet-to-white blood cell ratio on short-term mortality events in patients hospitalized with acute decompensated heart failure: evidence from a cohort study from Jiangxi, China.Frontiers in cardiovascular medicine · 2025Article
- Carbohydrate antigen 125 on epicardial fat and its association with local inflammation and fibrosis-related markers.Journal of translational medicine · 2024Article
- Diagnostic approach to heart failure in Türkiye.Turkish journal of medical sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute heart failure (AHF) is a complex clinical syndrome that requires prompt diagnosis, risk stratification and effective treatment strategies to reduce morbidity and mortality. Biomarkers are playing an increasingly important role in this process, offering valuable insights into the underlying pathophysiology and facilitating personalised patient management. This review summarises the significance of various biomarkers in the context of AHF, with a focus on their clinical applications to stratify risk and potential for guiding therapy choices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.